NENG SITI SOPIAH, - (2022) ANALISIS EFEKTIVITAS BIAYA PENGGUNAAN OBAT PADA PASIEN RAWAT INAP PENYAKIT COVID-19 KATEGORI SUSPEK NON-COMORBID DENGAN TERAPI OBAT KOMBINASI ANTIVIRUS DAN ANTIBIOTIK DI RUMAH SAKIT TNI AU dr. M. SALAMUN KOTA BANDUNG PERIODE JULI – DESEMBER 2021. Skripsi thesis, Sekolah Tinggi Farmasi Indonesia.
![[img]](http://repository.stfi.ac.id/style/images/fileicons/text.png) |
Text
S_PSSF_A182020_Title.pdf Download (539kB) |
|
Text
S_PSSF_A182020_Chapter1.pdf Restricted to Repository staff only Download (141kB) |
|
Text
S_PSSF_A182020_Chapter2.pdf Restricted to Repository staff only Download (515kB) |
|
Text
S_PSSF_A182020_Chapter3.pdf Restricted to Repository staff only Download (255kB) |
|
Text
S_PSSF_A182020_Chapter4.pdf Restricted to Repository staff only Download (338kB) |
|
Text
S_PSSF_A182020_Chapter5.pdf Restricted to Repository staff only Download (127kB) |
|
Text
S_PSSF_A182020_Appendix.pdf Restricted to Repository staff only Download (1MB) |
Abstract
COVID-19 merupakan penyakit menular yang disebabkan oleh virus SARS-CoV2. Biaya pengobatan nya memerlukan biaya yang besar. Penelitian ini bertujuan untuk menganalisis efektivitas biaya dalam penggunaan obat pada pasien rawat inap penyakit COVID-19 kategori suspek non-comorbid dengan terapi kombinasi antivirus dan antibiotik di RS TNI AU dr. M. SALAMUN Periode Juli – Desember 2021. Penelitian ini menggunakan metode deskriptif non analitik. Pengambilan data dilakukan secara retrospektif dengan mengakses data rekam medis. Sampel yang memenuhi kriteria inklusi pada penelitian ini adalah sebanyak 48 pasien. Analisis efektivitas biaya dilakukan dengan menghitung Average Cost Effectivness Ratio (ACER) dan Incremental Cost Effectivness Ratio (ICER), selanjutnya dilakukan analisis sensitivitas untuk mengetahui parameter yang mempengaruhi efektivitas biaya dengan meningkatkan biaya obat menjadi 2,5%, 5%, 7,5% . Hasil analisis menunjukan penggunaan kombinasi antivirus dan antibiotik pada pasien COVID-19 yaitu ada 16 variabel dan pengobatan yang paling cost effective (hemat biaya) adalah kombinasi ceftriaxone inj inj dengan oseltamivir didapat sebesar ACER = Rp1.005.724, kombinasi azitromicyn dengan ceftriaxone inj inj didapat sebesar ICER = Rp.-2.113.412. Hasil analisis sensitivitas menunjukan bahwa tidak adanya perubahan terhadap ACER dan ICER meskipun harga obat ditingkatkan sampai dengan 7,5% dan kombinasi ceftriaxone inj inj dengan oseltamivir tetap paling cost effective. --- COVID-19 is an infectious disease caused by the SARS-CoV-2 virus. The cost of his treatment requires a large amount of money. This study aims to analyze the cost-effectiveness of drug use in hospitalized patients with COVID-19 in the category of non-comorbid suspects with combination antiviral and antibiotic therapy at the Indonesian Air Force Hospital dr. M. SALAMUN Period July – December 2021. This study uses a non-analytic descriptive method. Data collection was carried out retrospectively by accessing medical record data. Samples that met the inclusion criteria in this study were 48 patients. Costeffectiveness analysis was carried out by calculating the Average Cost Effectiveness Ratio (ACER) and Incremental Cost Effectiveness Ratio (ICER), then a sensitivity analysis was carried out to determine the parameters that affect cost-effectiveness by increasing drug costs to 2.5%, 5%, 7.5%. . The results of the analysis show the use of combinations of antivirals and antibiotics in COVID-19 patients, namely there are 16 variables and the most cost-effective (cost-effective) treatment is the combination of ceftriaxone inj with oseltamivir obtained at ACER = Rp. 1.005.724, the combination of azithromycin with ceftriaxone inj. is obtained at ICER = Rp.-2.113,412. The results of the sensitivity analysis showed that there was no change in ACER and ICER even though the drug price was increased up to 7.5% and the combination of inj ceftriaxone with oseltamivir remained the most cost-effective.
| Item Type: | Thesis (Skripsi) |
|---|---|
| Uncontrolled Keywords: | COVID-19, analisis efektivitas biaya, Average Cost Effectivness (ACER), Incremental Cost Effectivness Ratio (ICER) --- COVID-19, cost-effectiveness analysis, Average Cost Effectiveness (ACER), Incremental Cost Effectiveness Ratio (ICER) |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine |
| Divisions: | Program Studi S1 Farmasi |
| Depositing User: | pustakawan - - |
| Date Deposited: | 14 Sep 2024 13:34 |
| Last Modified: | 14 Sep 2024 13:34 |
| URI: | http://repository.stfi.ac.id/id/eprint/1204 |
Actions (login required)
 |
View Item |
